Given that IL-8 is also strongly associated with an increase in ASMC migration in such contexts, there is a growing interest in exploring pharmacological targeting of this cytokine or its receptors as a potential leading therapeutic approach to prevent irreversible bronchial remodeling in numerous patients with COPD and asthma. This evidence concerns the gene CXCL8 and chronic obstructive pulmonary disease.